Special Issue "Pathophysiology and Treatment of Gallbladder Cancer"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: 31 January 2022.

Special Issue Editors

Dr. Philip De Reuver
E-Mail Website
Guest Editor
Department of Surgery, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands
Interests: biliary disease; rare cancers; shared decision making; health care efficiency
Dr. Chella van der Post
E-Mail Website
Guest Editor
Department of Pathology, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands
Interests: detection; clinical

Special Issue Information

Dear Colleagues,

Gallbladder cancer (GBC) is a rare and highly lethal neoplasm of the biliary tract. GBC demonstrates significant geographic, age-, gender-, and ethnicity-related differences in incidence, but the cause of GBC and it’s pathophysiology is not well understood. (Epi)Genetics or environmental factors may play an essential role in the development of GBC. Other possible risk factors include cholelithiasis, obesity, gallbladder polyps, chronic infections, and an abnormal pancreaticobiliary duct junction. However, most patients with GBC do not have any of the known risk factors apart from age. It could be hypothesized that different causes of gallbladder cancer also imply different treatment strategies.

This Special Issue will focus on the current insights into the pathophysiology, treatment and predictive factors for survival of gallbladder cancer in different geographic area’s.  This issue aims to improve our understanding in the development of GBC. We look forward to your contributions.

Dr. Philip De Reuver
Dr. Chella van der Post
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gallbladder cancer
  • pathophysiology
  • risk factors

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

Article
Quality Assessment of Gallbladder Cancer Pathology Reports: A Dutch Nationwide Study
Cancers 2021, 13(12), 2977; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13122977 - 14 Jun 2021
Viewed by 740
Abstract
Adequate reporting of pathological findings is essential for optimal patient management and to perform high-quality research. The aim of this study was to assess the completeness of pathology reports of gallbladder cancer (GBC) at the nationwide level to assess guideline adherence and make [...] Read more.
Adequate reporting of pathological findings is essential for optimal patient management and to perform high-quality research. The aim of this study was to assess the completeness of pathology reports of gallbladder cancer (GBC) at the nationwide level to assess guideline adherence and make recommendations for improvement. A retrospective population-based cohort of GBC patients diagnosed in the Netherlands from 2000 to 2019 was collected using data from the Dutch Cancer Registry and the nationwide network and registry of histology. Pathology reports were scored on the presence and content of essential and optional items according to the Dutch consensus-based guideline on biliary tract cancer. By histopathological review of cases, we compared findings with the conclusion of the corresponding pathology report. All pathology reports (n = 849) had a narrative, nonstructured format. Overall completeness was low. Information on key prognostic factors, such as tumor side (hepatic vs. serosal), status of cystic duct and liver surgical margins and venous and perineural invasion, was frequently lacking (80%, 23%, 59%, 74% and 74% missing, respectively). Whereas certain items were often missing from the report, they could be retrospectively detected in a substantial proportion of cases during pathology review (n = 738). In conclusion, significant improvements could be made in the reporting of GBC in the Netherlands. Synoptic reporting could greatly enhance the completeness of reports, as already demonstrated for tumor types. Full article
(This article belongs to the Special Issue Pathophysiology and Treatment of Gallbladder Cancer)
Show Figures

Graphical abstract

Other

Jump to: Research

Systematic Review
Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications
Cancers 2021, 13(21), 5257; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13215257 - 20 Oct 2021
Viewed by 643
Abstract
Due to the fast progression in molecular technologies such as next-generation sequencing, knowledge of genetic alterations in gallbladder cancer (GBC) increases. This systematic review provides an overview of frequently occurring genetic alterations occurring in GBC and their possible therapeutic implications. A literature search [...] Read more.
Due to the fast progression in molecular technologies such as next-generation sequencing, knowledge of genetic alterations in gallbladder cancer (GBC) increases. This systematic review provides an overview of frequently occurring genetic alterations occurring in GBC and their possible therapeutic implications. A literature search was performed utilizing PubMed, EMBASE, Cochrane Library, and Web of Science. Only studies reporting genetic alterations in human GBC were included. In total, data were extracted from 62 articles, describing a total of 3893 GBC samples. Frequently detected genetic alterations (>5% in >5 samples across all studies) in GBC for which targeted therapies are available in other cancer types included mutations in ATM, ERBB2, and PIK3CA, and ERBB2 amplifications. High tumor mutational burden (TMB-H) and microsatellite instability (MSI-H) were infrequently observed in GBC (1.7% and 3.5%, respectively). For solid cancers with TMB-H or MSI-H pembrolizumab is FDA-approved and shows an objective response rates of 50% for TMB-H GBC and 41% for MSI-H biliary tract cancer. Only nine clinical trials evaluated targeted therapies in GBC directed at frequently altered genes (ERBB2, ARID1A, ATM, and KRAS). This underlines the challenges to perform such clinical trials in this rare, heterogeneous cancer type and emphasizes the need for multicenter clinical trials. Full article
(This article belongs to the Special Issue Pathophysiology and Treatment of Gallbladder Cancer)
Show Figures

Figure 1

Back to TopTop